SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cheryl Galt who wrote (1303)2/4/2000 3:41:00 PM
From: Torben Noerup Nielsen  Read Replies (1) of 2001
 
Cheryl,

Thanks, I just printed out a copy of it and perused it. What's the most interesting to me is that their price target of $25 is based on a 7.5 multiple of revenues. I believe biotechnology firms have an average multiple greater than 20. And this is for ADCON revenues alone.

If Perceptin works out well and a deal is made, $75 is not an unreasonable valuation.

I'm heading for a very simple portfolio. About 50% GLIA and about 50% NBIX with a few little odds and ends thrown in. Sometimes I buy 1,000 shares of an issue just to remind me to pay attention to them. The market is a wonderful reminder service....

Thanks, Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News